South African Row Over Sweeping Powers For Zuma

27 August 1997

New drug legislation sent to Parliament by South African HealthMinister Nkosazana Zuma has created another furious row between the drug industry and the Health Department.

The legislation proposes, inter alia, an elimination of all patent rights for pharmaceuticals at the Minister's discretion, and the specific use of parallel imports, which is a further violation of the World Trade Agreement on intellectual property.

Dissatisfaction was also expressed against "onerous terms" of generic substitution, making the substitution of generic versions of innovative drugs mandatory rather than allowable.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight